10 PDL BioPharma Analyst Ratings, Earnings, Dividends and Insider Trades | $PDLI | NASDAQ:PDLI | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact PDL BioPharma Company Profile (NASDAQ:PDLI) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for PDL BioPharma (NASDAQ:PDLI) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 2 Hold Rating(s)Consensus Rating:Hold (Score: 2.00)Consensus Price Target: $8.75 (5.80% upside) Analysts' Ratings History for PDL BioPharma (NASDAQ:PDLI) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare3/6/2014ZacksReiterated RatingNeutral -> Neutral$9.00View 1/3/2014ZacksReiterated RatingNeutral -> Neutral$9.00View 11/8/2013ZacksReiterated RatingNeutral -> Neutral$8.50View 10/18/2013ZacksReiterated RatingNeutral -> Neutral$8.50View 8/13/2013ZacksReiterated RatingNeutral -> Neutral$8.75View 5/16/2013ZacksReiterated RatingNeutral -> Neutral$8.75View 5/14/2013Piper JaffrayInitiated CoverageNeutral$8.50View 3/6/2013JPMorgan Chase & Co.Lower Price TargetNeutral$7.00 -> $6.00View 1/15/2013Credit SuisseDowngradeNeutral -> Underperform$6.50 -> $6.00View 1/3/2013Janney Montgomery ScottInitiated CoverageNeutral$7.00View 1/2/2013Janney Montgomery ScottInitiated CoverageNeutralView 12/6/2012Credit SuisseInitiated CoverageNeutralView 11/12/2012Credit SuisseInitiated CoverageNeutral$6.50View 8/24/2012ThinkEquityInitiated CoverageHoldView (Data available from 3/9/2012 forward) Earnings History for PDL BioPharma (NASDAQ:PDLI)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare3/3/2014Q413$0.43$0.39$115.22 million$110.10 millionViewN/AView 11/6/2013Q313$0.37$0.36$97.09 million$97.30 millionViewN/AView 8/8/2013Q2 2013$0.54$0.62$138.20 million$143.60 millionViewN/AView 5/9/2013Q1 2013$0.35$0.36$91.69 million$91.80 millionViewN/AView 3/1/2013Q4 2012$0.31$0.34$86.08 million$86.10 millionViewN/AView 11/5/2012Q312$0.33$0.32$85.03 million$85.20 millionViewN/AView 8/2/2012$0.44$0.52ViewN/AView 5/3/2012$0.27$0.29ViewN/AView 2/23/2012$0.28$0.24ViewN/AView 11/9/2011$0.27$0.28ViewN/AView 7/27/2011$0.39$0.39ViewN/AView 4/27/2011$0.24$0.25ViewN/AView 2/28/2011$0.21$0.20ViewN/AView (Data available from 1/1/2011 forward) Dividend History for PDL BioPharma (NASDAQ:PDLI)AnnouncedPeriodAmountEx-Dividend DateRecord DatePayable DateShare1/31/2014quarterly$0.159/3/20149/5/20149/12/2014 1/31/2014quarterly$0.153/3/20143/5/20143/12/2014 1/31/2014quarterly$0.1512/3/201412/5/201412/12/2014 1/31/2014quarterly$0.156/3/20146/5/20146/12/2014 1/31/2013quarterly$0.1512/3/201312/5/201312/12/2013 1/31/2013quarterly$0.156/3/20136/5/20136/12/2013 1/31/2013quarterly$0.159/3/20139/5/20139/12/2013 1/30/2013quarterly$0.153/1/20133/5/20133/12/2013 (Data available from 1/1/2013 forward) Insider Trading History for PDL BioPharma (NASDAQ:PDLI)No insider trades for this company have been tracked by Analyst Ratings Network About PDL BioPharma PDL BioPharma, Inc. (PDL) is a is a biotech company. PDL is engaged in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The Company receives royalties based on sales of humanized antibody products marketed and may also receive royalty payments on additional humanized antibody products launched before final expiry in December 2014. It has entered into licensing agreements with numerous entities that are independently developing or have developed humanized antibodies under which it has licensed certain rights under its Queen et al. patents to make, use, sell, offer for sale and import humanized antibodies. Headlines: (3/5) PDL BioPharma Misses on Q4 Earnings (3/4) PDL BioPharma Announces Conversion Rate Adjustments for Convertible Notes (3/3) PDL BioPharma Announces Fourth Quarter and Full Year 2013 Financial Results (2/28) PDL BioPharma, Inc. (PDLI) Ex-Dividend Date Scheduled for March 03, 2014 (3/3) PDL BioPharma Q4 Results Miss Estimates (2/18) PDL BioPharma and Paradigm Spine Complete a $75 Million Financing Transaction (2/24) PDL BioPharma to Announce Fourth Quarter and Full Year 2013 Financial Results on March 3, 2014 (3/4) Press Release Industry, Sector and Symbol: Sector: Healthcare Industry: Biotechnology Sub-Industry: Biotechnology Exchange: NASDAQ Symbol: PDLI CUSIP: 69329Y10 Key Metrics: Previous Close: $8.3650 Day Moving Average: $8.6409200 Day Moving Average: $8.4062 P/E Ratio: 5.04P/E Growth: 0.30Market Cap: $1.326BCurrent Quarter EPS Consensus Estimate: $2.00 EPS Additional Links: View PDLI on Google FinanceView PDLI on Yahoo FinanceView PDLI's Company Profile on ReutersSearch for PDL BioPharma Inc. on Google PDL BioPharma (NASDAQ:PDLI) Chart for Sunday, March, 9, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.